Rigel Pharmaceuticals, Inc.
Rigel Pharmaceuticals develops therapies for patients with hematologic disorders and cancer. Products include Tavalisse, Rezlidhia, and GAVRETO. Rezlidhia treats relapsed or refractory AML with IDH1 mutation. GAVRETO treats metastatic RET fusion-positive lung and thyroid cancers. The company also develops R289, an oral IRAK1/4 Inhibitor, in Phase 1b trials.
Overview
Strengths
- With an appreciation Potential of 65.06%, based on our fundamental analysis, it suggests the stock may be undervalued.
- Current Price to Earnings Ratio (2.35) is lower than the sector mean (91.15).
- Price to book ratio (2.21) is lower than the sector mean (24.44).
- The company has high returns. ROIC (17.05%) is higher than the sector mean (6.02%).
- EV/EBITDA (6.65) is lower than the sector mean (85.60).
- EV/EBIT (6.78) is lower than the sector mean.
- Price to free cash flow (11.41) is lower than the sector mean.
- Strong EBITDA Margin of 35.34%.
Weaknesses
- No significant weaknesses identified based on the analyzed metrics.
Key Financial Data